The use of granulocyte colony–stimulating factors in a Canadian outpatient setting

Por Fine, S., Koo, M., Gill, T., Marin, M., Poulin–Costello, M., Barron, R., Mittmann, N.
Publicado em 2014

A Randomized, blinded assessor study to Evaluate the efFIcacy and safety of etanercept 50 mg once weekly plus as Needed topical agent vs. Etanercept 50 mg twice weekly in patients...

Por Papp, KA, Barber, K, Bissonnette, R, Bourcier, M, Lynde, CW, Poulin, Y, Shelton, J, Toole, J, Vieira, A, Poulin-Costello, M
Publicado no J Eur Acad Dermatol Venereol (2015)

Improvements in patient‐reported outcomes in patients with psoriasis receiving etanercept plus topical therapies: results from REFINE

Por Papp, K.A., Barber, K., Bissonnette, R., Bourcier, M., Lynde, C.W., Poulin, Y., Shelton, J., Garces, K., Toole, J., Poulin‐Costello, M.
Publicado no J Eur Acad Dermatol Venereol (2015)

Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis

Por Eisen, T, Ahmad, T, Flaherty, K T, Gore, M, Kaye, S, Marais, R, Gibbens, I, Hackett, S, James, M, Schuchter, L M, Nathanson, K L, Xia, C, Simantov, R, Schwartz, B, Poulin-Costello, M, O'Dwyer, P J, Ratain, M J
Publicado em 2006